Soligenix (NASDAQ:SNGX) released its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.11) EPS for the quarter, meeting analysts’ consensus estimates of ($0.11), MarketWatch Earnings reports. Soligenix had a negative return on equity of 176.04% and a negative net margin of 120.14%. The company had revenue of $1.40 million during the quarter, compared to analysts’ expectations of $1.40 million.
Soligenix stock traded down $0.04 during midday trading on Friday, reaching $1.10. The company’s stock had a trading volume of 140,125 shares, compared to its average volume of 219,986. Soligenix has a 52-week low of $0.91 and a 52-week high of $3.70.
A number of equities research analysts have commented on the company. Maxim Group reiterated a “buy” rating and issued a $4.00 price target on shares of Soligenix in a research note on Thursday, September 13th. ValuEngine upgraded Soligenix from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st.
COPYRIGHT VIOLATION WARNING: “Soligenix (SNGX) Issues Earnings Results” was originally posted by Week Herald and is the property of of Week Herald. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://weekherald.com/2018/11/10/soligenix-sngx-issues-earnings-results.html.
Soligenix Company Profile
Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer.
Further Reading: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.